Lack of harmonization on impurities a concern, says industry group

By Gareth Macdonald

- Last updated on GMT

Related tags Vice president

Lack of harmonization on impurities a concern, says industry group
An industry consortium has asked the USP to delay new elemental impurities chapters on concerns that lack of harmonization with ICH Q3D will create compliance difficulties, shortages and additional costs.

The United States Pharmacopeial convention (USP) announced the new guidelines in May​ last year, commenting that the existing testing requirements are based on a "technique not sufficiently sensitive to detect a number of impurities at levels known to be toxic​."

At the time Anthony DeStefano - USP's senior VP of compendial services - told in-Pharmatechnologist.comt the drug industry would have enough time to adapt to the new requirements, which come into effect in May 2014.

This view is not shared by drug and API makers according to an industry group - whose members include IPEC Americas, IPEC Europe, GPhA, CHPA, SOCMA’s BPTF and the NJPQCA - which asked the USP to delay the implementation of its rules on impurities earlier this week.

The group's main concern is that the USP will introduce its requirements before the International Conference on Harmonisation's (ICH) completes its own work on elemental impurities.

Despite the fact that the ICH guideline is still in the early draft form, the USP has decided unilaterally to move forward with implementation of their General Chapters <232> and <233> and call for implementation of the USP Elemental Impurity General Chapter requirements by May 1, 2014.

Since this is likely to be before the ICH Q3D guideline is expected to be completed, industry has serious concerns that moving forward with the USP requirements without harmonization with the ICH Q3D guideline could lead to regulatory and compliance issues, potential supply interruptions and added costs to manufacturers and patients​.”

The group also said it plans to meet with the US Food and Drug Administration (FDA) this month to discuss its concerns, adding that it has asked the agency to help develop a harmonized approach to the implementation timeline.

It is hoped that the Coalition’s efforts will ultimately result in harmonization of the USP’s requirements with those being developed by the ICH Q3D EWG.

"As we move towards this goal the Coalition will continue to work on additional risk assessment tools, data collection and educational activities in the future to assist in the implementation of these requirements​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more